In a research report published today, Canaccord Genuity analyst Mark Massaro weighed in with some of his opinions on EXACT Sciences Corporation (NASDAQ:EXAS) following the …
Canaccord Genuity analyst Mark Massaro offered some commentary on EXACT Sciences Corporation (NASDAQ:EXAS) ahead of the company’s first ever Analyst Day, which will take …
In a research report issue today, Canaccord analyst Mark Massaro maintained a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $30 price target, after the company announced a …
EXACT Sciences Corporation (NASDAQ:EXAS) shares increased 2.51% to $28.
EXACT Sciences Corporation (NASDAQ:EXAS) announced that data supporting its stool DNA (sDNA) screening platform for colorectal cancer and other screening techniques for the detection …
Exact Sciences Corporation (NASDAQ:EXAS) surged 11% today after the company reported first-quarter results with revenues beating consensus expectations. In reaction, Canaccord’s healthcare analyst Mark Massaro reiterated a Buy rating on the …
Exact Sciences Corporation (NASDAQ:EXAS) announced its business and financial results for the quarter endingMarch 31, 2015, reporting that 11,000 Cologuard tests were completed and …
Exact Sciences Corporation (NASDAQ:EXAS) shares are up 9% today after Anthem Blue Cross announced a positive coverage decision for Exact’s Cologuard test. Anthem is the largest …
Canaccord Genuity’s healthcare analyst Mark Massaro weighed in today with a few insights on EXACT Sciences Corporation (NASDAQ:EXAS), after the stock plunged following the company’s fourth-quarter call. The …
